← Back to patent-cliff list
Tigulixostat
Tier C — Watch / tradeTigulixostat
Lg Chemical Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：XO
Indications (approved)：Hyperuricaemia, Gout, 痛风性关节炎, Heart disease, 代谢病
Regional status
US
Phase III
2022-10-25
EU
Phase III
2023-03-30
China
Phase III
2026-03-17
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Tigulixostat?
Approved indications include: Hyperuricaemia, Gout, 痛风性关节炎, Heart disease, 代谢病.
When does the Tigulixostat patent expire?
No public expiry year is available for Tigulixostat yet; this page updates once verified.
How do I get a quote for Tigulixostat intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03